BGMD: BG Medicine, Inc. Twitter

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 9, 9:45 AM BG Medicine (BGMD): Q1 EPS of -$0.21 beats by $0.06. Revenue of $888K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, April 10, 10:31 AM BG Medicine (BGMD +3.6%) trades up after announcing earlier that partner Abbott (ABT +0.2%) has obtained a CE Mark for its Galectin-3 assay run on the Architect immunochemistry platform. The Galectin-3 assay is an indicator that assesses the risk for readmission in heart failure. BGMD is partnering with four diagnostic instrument manufacturers to commercialize automated versions of the test, making it available in several European countries, pending country registration. Comment! [Healthcare, On the Move, Global & FX]
Wednesday, March 13, 10:19 AM BG Medicine (BGMD +14%) ramps higher after beating Q4 EPS estimates on a narrower-than-expected loss. Revenue jumped nearly 250% Y/Y, driven largely by increased sales of its BGM Galectin-3(R) test, with product margins increasing 10% over the same period from 60% to 70%. Net losses also decreased by 38% Y/Y from $4.7M to $2.9M, primarily from an adjustment of accrued R&D expenses. Comment! [Healthcare, Earnings, On the Move]
Wednesday, March 13, 9:10 AM Premarket gainers: BGMD +15%. SUMR +10%. PPHM +5%.
Losers: SPPI -36%. VELT -32%. ASMI -13%. EXPR -13%. TEU -10%. DOLE -7%. WFR -6%. Comment! [On the Move]
Wednesday, March 13, 7:51 AM BG Medicine (BGMD): Q4 EPS of -$0.14 beats by $0.18. Revenue of $1.07M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, February 27, 10:39 AM BG Medicine (BGMD +11%) ramps higher this morning after announcing the publication of two studies demonstrating the benefit of repeated galectin-3 testing as a tool in the assessment of patients with heart failure. The studies demonstrate that periodic evaluation of galectin-3 levels can help clinicians identify those at greater risk of unplanned hospital admission and cardiovascular morbidity and mortality. Comment! [Healthcare, On the Move]
Friday, January 25, 12:45 PM Midday top 10 gainers: EFII +15%. OSK +15%. SHIP +15%. SYNA +15%. LSCC +14%. NFLX +14%. QLGC +13%. BDR +13%. CIMT +13%. CRUS +12%.
Midday top 10 Losers: NFBK -27%. ZN -26%. SCSS -18%. SCSC -15%. BGMD -15%. CTRP -13%. HTCH -11%. EGHT -10%. ARWR -8%. MSL -7%. Comment! [On the Move]
Friday, January 25, 9:10 AM Premarket gainers: INFA +10%. TPX +10%. ECTE +9%. OSK +8%. STP +6%. THLD +7%. SNE +6%.
Losers: SCSS -15%. BGMD -15%. EGHT -10%. SFL -8%.
1 Comment [On the Move]
Friday, January 25, 8:02 AM BG Medicine (BGMD) -10% premarket after announcing a secondary to price this morning and its intention to purchase up to $12M of its stock from a big holder, Aspire Capital. Comment! [Healthcare, On the Move]
Thursday, January 3, 12:45 PM Midday top 10 gainers: SPWR +38%. VISN +30%. MDCI +20%. FORD +20%. BGMD +19%. TSL +19%. CRDC +19%. FOLD +19%. TELK +18%. JASO +16%.
Midday top 10 Losers: LPH -73%. ALLT -23%. MLNX -14%. FDO -12%. AMPL -12%. TRIT -11%. PKT -10%. SSI -9%. LODE -9%. HPJ -9%. 1 Comment [On the Move]
Thursday, January 3, 9:10 AM Premarket gainers: BGMD +22%. SPWR +16%. ALU +10%. CBMX +10%. FOLD +8%. TASR +6%. LDK +6%. ZGNX +5%.
Losers: MLNX -18%. ALLT -10%. FDO -10%. KERX -6%. BIIB -6%. Comment! [On the Move]
Thursday, January 3, 8:28 AM BG Medicine (BGMD) rockets 24% after saying it has received the EU's CE mark for the first automated version of the company's Galectin-3 blood test for improving the management of heart conditions. BG is working with four partners to commercialize the test, including Abbott Labs (ABT) and Siemens (SI). The EU approval comes just a week after SA author Robert Fabian called BG Medicine a "hidden gem." (PR) Comment! [Healthcare, On the Move]
Wednesday, January 2, 5:37 PM After-hours top gainers, as of 5:15 p.m.: BGMD +14%. KYAK +8%. SZYM +6%. LNDC +4%. NAVB +3%.
After-hours top losers: MLNX -16%. RMBS -12%. ESIO -8%. AUO -6%. OME -4%. 1 Comment [On the Move]
Wednesday, December 12, 2012, 9:10 AM Premarket gainers: YMI +79%. DSTI +15%. SCMP +11%. ACAD +9%. BGMD +10%.
Losers: RSOL -16%. CIE -11%. MCP -6%. Comment! [On the Move]
Tuesday, December 11, 2012, 6:10 PM After-hours top gainers, as of 5:15 p.m.: RTEC +8%. DLB +6%. MCBC +4%. BGMD +4%. GEO +3%.
After-hours top losers: GEOS -12%. CIE -10%. EXAR -7%. NTSP -7%. ALXA -7%. 1 Comment [On the Move]
Tuesday, December 11, 2012, 12:45 PM Midday top 10 gainers: BGMD +146%. SOMX +75%. ACUR +56%. TNS +43%. ULBI +18%. MEAD +16%. ESYS +15%. SZYM +14%. GTXI +13%. CLWR +12%.
Midday top 10 Losers: CBMX -11%. ESIO -11%. AMCN -9%. SEV -9%. GGAL -8%. SPW -8%. TELK -7%. [[JW-A]] -7%. MGLN -7%. SXC -7%. 2 Comments [On the Move]

BGMD BG Medicine, Inc.

BGMD

BG Medicine, Inc.